Clinical trials: Myelogenous Leukemia, Acute
Acute Myeloid Leukemia
Safety, Efficacy and Pharmacokinetics of an Antifungal in Patients Undergoing Chemotherapy
Patients who undergo chemotherapy for leukemia will receive study medication for prevention of fungal infections. The study investigates the safety and tolerability of two different dosages, the efficacy in prevention of fungal…
- Trial name
- NCT00413439
- Testing
- Isavuconazole
- Where
- 4 sites in Germany
- Volunteers
- 18 people
- Sponsor
- Basilea Pharmaceutica
Chronic Myeloid Leukemia in Myeloid Blast Crisis, Untreated Adult Acute Myeloid Leukemia
Nilotinib-Chemotherapy in CML Myeloid BP or Bcr-abl(+) AML
The current standard therapy in previously untreated adults with chronic phase (CP) of CML is imatinib and the result of long-term follow-up of IRIS study proves that imatinib for CML CP is reasonable therapy.(1, 2) However, some…
- Trial name
- NICE-BORA (NCT01690065)
- Testing
- Nilotinib+AD induction
- Where
- 2 sites in South Korea
- Volunteers
- 46 people
- Sponsor
- Ulsan University Hospital
Acute Myeloid Leukemia
Alvocidib Biomarker-driven Phase 2 AML Study
The purpose of this two-stage Phase 2 study is to assess the clinical response (Complete Remission) of ACM (Alvocidib/Cytarabine/Mitoxantrone) compared to CM (Cytarabine/Mitoxantrone) treatment in refractory or relapsed AML…
- Trial name
- NCT02520011
- Testing
- Alvocidib, Cytarabine, Mitoxantrone
- Where
- 38 sites in United States, Canada and 2 more
- Volunteers
- 104 people
- Sponsor
- Sumitomo Pharma America, Inc.
Relapsed/Refractory Acute Myeloid Leukemia(AML)
A Clinical Study to Explore the Safety and Efficacy of CT0991 in Relapsed/Refractory Acute Myeloid Leukemia
A Clinical Study to Investigate the Safety and Efficacy of CT0991 in Patients with Relapsed/Refractory Acute Myeloid Leukemia
- Trial name
- CT0991 (NCT06709131)
- Testing
- CAR-T cells（ chimeric antigen receptor T cells）
- Where
- China
- Volunteers
- 24 people
- Sponsor
- He Huang
Non Hodgkin Lymphoma, Richter Transformation
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
This is a Phase 1, multi-center, open-label study with a dose-escalation phase (Phase 1a) and a cohort expansion phase (Phase 1b), to evaluate the safety, tolerability, and PK profile of LP-118 under a once daily oral dosing…
- Conditions
- Non Hodgkin Lymphoma, Richter Transformation, Multiple Myeloma, T-cell-prolymphocytic Leukemia
- Trial name
- NCT04771572
- Testing
- LP-118
- Where
- 8 sites in United States
- Volunteers
- 100 people
- Sponsor
- Newave Pharmaceutical Inc
Acute Myeloid Leukaemia (AML), Acute Lymphoblastic Leukemia ALL
Safely Delivered Targeted High-dose Irradiation Followed by Adoptive Immunotherapy with Regulatory and Conventional T Cells to Increase Potency of Hematopoietic Stem Cell Transplantation in High-risk Acute Leukemia
The study is a monocentric, interventional study that evaluates the efficacy of allogeneic HLA-matched or haploidentical transplantation consisting of an irradiation-based conditioning regimen coupled with donor Treg/Tcon…
- Conditions
- Acute Myeloid Leukaemia (AML), Acute Lymphoblastic Leukemia ALL, High Risk Leukaemia, Leukaemia Relapse
- Trial name
- SHARP (NCT06845592)
- Testing
- total marrow/lymphoid irradiation
- Where
- Italy
- Volunteers
- 51 people
- Sponsor
- University Of Perugia
TP53-mutated MDS and AML, Allogeneic Hematopoietic Stem Cell Transplantation
Maintenance Therapy With Selinexor and Azacitidine in TP53 Mutant AML/MDS After Transplantation
This study aims to explore the safety and efficacy of selinexor combined with azacitidine for maintenance therapy in TP53 mutant AML/MDS patients following transplantation.
- Trial name
- NCT07094464
- Testing
- Maintenance Therapy with Selinexor and Azacitidine
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Daihong Liu
Leukemia
Genetics Study of Tissue Collected From Patients With Acute Myeloid Leukemia
RATIONALE: Collecting and storing samples of tissue and blood from patients with cancer to study in the laboratory may help doctors learn more about changes that may occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00898092
- Testing
- microarray analysis, molecular genetic technique, mutation analysis
- Where
- United States
- Volunteers
- 735 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Advanced Hematologic Malignancies
Study to Evaluate Safety, Tolerability, Maximum Tolerated Dose (MTD), Efficacy, and Pharmacokinetics (PKs) of CPI-613 Given Twice Weekly for Three Consecutive Weeks in Patients With Advanced Hematologic Malignancies
Chemotherapy resistance is a major cause of death in patients with advanced hematologic malignancies. The proposed novel mechanism of action, non-cross resistance with chemotherapeutic agents currently used in the clinic, and…
- Trial name
- NCT01034475
- Testing
- CPI-613
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Wake Forest University Health Sciences
Acute Myeloid Leukemia, Myeloid and Monocytic Leukemia
Multi-Ctr PII Cmb.Modality Tx Ruxolitinib, Decitabine, and DLI for Post HSCT in AML/MDS
This is a multi-center, single-arm, open-label, phase II trial for the frontline treatment of relapsed AML or MDS following allo-HCT. Eligible subjects will receive up to 4 cycles of combined modality treatment.
- Conditions
- Acute Myeloid Leukemia, Myeloid and Monocytic Leukemia, Myelodysplastic Syndromes
- Trial name
- NCT04055844
- Testing
- Decitabine, Ruxolitinib, Donor Lymphocyte Infusion (DLI)
- Where
- 3 sites in United States
- Volunteers
- 14 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Acute Myelogenous Leukemia, Chronic Myelomonocytic Leukemia
LILRB4 STAR-T Cell Therapy for Monocytic Leukemia
This is a single-center,single-arm,open-label phase I clinical study to determine the safety and efficacy of LILRB4 STAR-T cells in Monocytic Leukemia subjects.
- Trial name
- NCT05739409
- Testing
- LILRB4 STAR-T cells injection
- Where
- 2 sites in China
- Volunteers
- 1 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
AML (Acute Myeloid Leukemia)
Clinical Study of Anti-CLL1-CD33-NKG2D Bicephali CAR-T for Relapsed/Refractory Acute Myeloid Leukemia
This study is a clinical trial designed to evaluate the safety and efficacy of a new type of CAR-T cell therapy for patients with relapsed/refractory acute myeloid leukemia (AML).
- Trial name
- AML CAR-T (NCT07370064)
- Testing
- CAR-T
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Xuzhou Medical University
Bloodstream Infection, Acute Myeloid Leukemia
Efficacy of Antibiotic Short Course for Bloodstream Infections in Acute Myeloid Leukemia Patients With Febrile Neutropenia
There is no specific recommendation about antimicrobial treatment length for documented infections in chemotherapy induced febrile neutropenia.
- Conditions
- Bloodstream Infection, Acute Myeloid Leukemia, Febrile Neutropenia
- Trial name
- NCT04910698
- Testing
- Antibiotic
- Where
- France
- Volunteers
- 104 people
- Sponsor
- Poitiers University Hospital
Chronic Myelomonocytic Leukemia, Recurrent Acute Myeloid Leukemia
Prexasertib (LY2606368), Cytarabine, and Fludarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
This phase I trial studies the side effects and determine the best dose of prexasertib (LY2606368) when given together with cytarabine and fludarabine in patients with acute myeloid leukemia or high-risk myelodysplastic syndrome…
- Conditions
- Chronic Myelomonocytic Leukemia, Recurrent Acute Myeloid Leukemia, Recurrent High Risk Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia
- Trial name
- NCT02649764
- Testing
- Cytarabine, Fludarabine Phosphate, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- M.D. Anderson Cancer Center
Acute Myeloid Leukemia, Advanced Myelodysplastic Syndromes
Busulfan, Melphalan, and Fludarabine With Peri-transplant Palifermin, Followed by a T-Cell Depleted Hematopoietic Stem Cell Transplant From HLA Matched or Mismatched Related or Unrelated Donors in Patients With Advanced Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)
This study will see if the researchers can lower that risk by giving the patient Palifermin. This drug helps protect the lining of the mouth, throat, and stomach.
- Trial name
- NCT00629798
- Testing
- Busulfan, Melphalan, Fludarabine, Anti-Thymocyte Globulin, Palifermin, Stem cell transplant
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Acute Myeloid Leukemia
Dasatinib in Combination With Chemotherapy for Relapsed or Refractory Core Binding Factor Acute Myeloid Leukemia
This study will examine the appropriate dose and side effects of dasatinib, when it is given with the standard of care chemotherapy for children and adolescents with Acute Myeloid Leukemia (AML).
- Trial name
- NCT02680951
- Testing
- Dasatinib, Fludarabine, Cytarabine
- Sponsor
- Emory University
Leukemia
4'-Thio-araC (Thiarabine) in Advanced Hematologic Malignancies
The goal of this clinical research study is to find the highest tolerable dose of 4'-thio-araC (thiarabine) that can be given to patients with advanced blood cancer.
- Trial name
- NCT01139151
- Testing
- 3 Day Thiarabine, 5 Day Thiarabine
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- M.D. Anderson Cancer Center
Leukemia
Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous or Acute Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses…
- Trial name
- NCT00002831
- Testing
- Filgrastim, Busulfan, Cyclophosphamide
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- M.D. Anderson Cancer Center
Acute Myeloid Leukemia (AML)
A Study of Oral Venetoclax Tablet in Combination With Subcutaneous Low-Dose Cytarabine (LDAC) Injection to Assess Adverse Events in Adult Japanese Participants With Acute Myeloid Leukemia (AML)
Acute Myeloid Leukemia (AML) is a cancer of the white blood cells which perform many functions, including fighting bacterial infections and defending the body against parasites.
- Trial name
- NCT04509622
- Testing
- Venetoclax, Cytarabine
- Where
- 16 sites in Japan
- Volunteers
- 14 people
- Sponsor
- AbbVie
Myelogenous Leukemia, Acute
Study of Iressa in Patients With Relapsed or Refractory Acute Myelogenous Leukemia
The purpose of this study is to determine how effective, and to what extent, Iressa is in the treatment of acute myelogenous leukemia.
- Trial name
- NCT00130702
- Testing
- gefitinib
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Dana-Farber Cancer Institute
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.